What did Eli Lilly's clinical trials for tirzepatide actually find?

What was the SURMOUNT programme actually designed to test?

Eli Lilly built the SURMOUNT programme around a specific scientific question: could a dual GIP and GLP-1 receptor agonist produce meaningfully greater weight loss than had been seen with single-pathway GLP-1 medicines? Tirzepatide activates two gut-hormone receptors involved in appetite regulation and blood-sugar control, slowing gastric emptying and increasing satiety. No other weight-loss medicine licensed in the UK works on both pathways simultaneously.

SURMOUNT-1 was the cornerstone study: 2,539 adults with a BMI of 30 or above (or 27 with at least one weight-related condition), all without type 2 diabetes, randomised to tirzepatide 5 mg, 10 mg, or 15 mg, or placebo. The trial ran for 72 weeks alongside a reduced-calorie diet and increased physical activity — reflecting the conditions under which tirzepatide is licensed to be used. A full breakdown of SURMOUNT-1's methodology and outcomes is available in the original SURMOUNT-1 publication in the New England Journal of Medicine.

Subsequent arms of the programme, including SURMOUNT-2 (adults with type 2 diabetes) and SURMOUNT-5, extended that evidence base considerably. You can read about what the trial results mean in practical terms in more detail if you want to go further into the data.

What did Eli Lilly's tirzepatide trials actually show about weight loss?

At the 15 mg maintenance dose in SURMOUNT-1, participants lost an average of around 20–21% of body weight over 72 weeks. Some analyses placed the figure slightly higher. These are averages across a population (individual results varied) and any legitimate discussion of the evidence should say so plainly. Results pages that quote a single headline number without that caveat are doing readers a disservice.

SURMOUNT-5, the direct head-to-head published in 2025, enrolled 751 adults with obesity but without type 2 diabetes and compared tirzepatide against semaglutide 2.4 mg over 72 weeks. Tirzepatide produced greater average weight reduction. NICE's committee discussion of TA1026 noted that indirect comparisons also favoured tirzepatide, and the SURMOUNT-5 data reinforced that picture. For context on how the two medicines compare across other factors, the Mounjaro clinical trial overview covers the broader SURPASS programme for diabetes as well.

The wider tirzepatide clinical programme (SURMOUNT and SURPASS combined) involved more than 10,000 participants, which is the figure behind references to Eli Lilly's large-scale evidence base. Attributing that total correctly matters: SURMOUNT-1 alone randomised 2,539 people, not tens of thousands.

How did Eli Lilly's trial data influence NICE's recommendation and UK prescribing?

NICE published its technology appraisal of tirzepatide (TA1026) in December 2024, updated in September 2025. The recommendation covers adults with a BMI of 35 or above plus at least one weight-related comorbidity, conditions such as high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. Lower BMI thresholds apply for South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds under UK guidance. You can read the full criteria in NICE's published appraisal of tirzepatide (TA1026).

The NHS is rolling out access in phases, the first cohort (BMI 40 or above with four or more of the five qualifying conditions) became eligible from June 2025. For people who do not yet meet NHS criteria, or who prefer not to wait, a private prescription route exists through regulated UK pharmacies. Understanding what a tirzepatide clinic actually involves is a reasonable next step if you are weighing up your options.

It is worth being clear about what the trial data does not tell you: it cannot tell any individual person how much weight they will lose. A prescriber assesses your full clinical picture before deciding whether tirzepatide is appropriate. On the cost of Mounjaro in the UK page, there is a fuller explanation of how private pricing works alongside what the NHS currently covers, useful context before you make any decisions.

How do Eli Lilly's findings compare with what actually arrives through a UK private prescription?

The tirzepatide used in Eli Lilly's SURMOUNT trials is the same medicine licensed and supplied in the UK as Mounjaro. The KwikPen arrives pre-filled, covering four weekly doses. When it comes through a regulated UK online pharmacy, it travels in plain, unbranded packaging via tracked DPD delivery, the tracking notification lands on your phone before the box does.

The licensed dose schedule starts at 2.5 mg. That starting dose exists to give your system time to adjust, not because 2.5 mg is where the trial results were seen, the meaningful weight-loss figures came from higher maintenance doses in people who titrated over several months. A prescriber decides the pace of that titration based on tolerability and response, not a fixed calendar. If you are thinking about starting and want to buy Mounjaro online, the full Mounjaro overview covers the licensed schedule in detail.

Anyone considering treatment based on the trial data deserves to know that tirzepatide carries a Black Triangle (▼) designation from the MHRA, meaning additional monitoring is in place as the medicine continues to be used in the wider population. Common side effects in the trials were gastrointestinal (nausea, diarrhoea, constipation, indigestion) typically most noticeable after starting or increasing a dose. The NHS tirzepatide medicines page sets out the full side-effect profile clearly, and it is worth reading before you consult a prescriber.

If you want to explore whether treatment is right for you, speaking to our prescribers is where that conversation starts.